Novo Nordisk, Sanofi and Eli Lilly face court in US over insulin prices

Two claims against the companies have been dropped, but one has been upheld.

Photo: Jacob Ehrbahn/Politiken

Novo Nordisk, Sanofi and Eli Lilly are facing racketeering charges in the US over their insulin prices.

The case is being adjudicated at a court in New Jersey, Fiercepharma reports.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs